Shots:
- Pfizer reported positive topline results from the P‑III (BASIS) study evaluating HYMPAVZI (marstacimab) in hemophilia A or B pts (N=48) with inhibitors, meeting the 1EP and demonstrating a 93% reduction in annualized bleeding rate (ABR) vs. on‑demand treatment (1.39 vs. 19.78; p < 0.0001) over 12mos.
- HYMPAVZI, a once‑weekly SC therapy that targets TFPI, showed clinically meaningful bleed protection across all 2EPs (spontaneous, joint, target joint, total bleeds), with a well‑tolerated safety profile
- Pfizer plans regulatory discussions and submissions, supporting HYMPAVZI as an anti‑TFPI therapy for Hemophilia withinhibitor pts., and offering a SC pre‑filled pen injection
Ref: Pfizer | Image: Pfizer | Press Release
Related News:- Arvinas and Pfizer Report the US FDA’s NDA Submission of Vepdegestrant for ESR1-Mutated Breast Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
